Monte Rosa Therapeutics, Inc. (GLUE) Free cash flow 2020–2025
Monte Rosa Therapeutics, Inc. (GLUE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$27.5MFY2025 · since FY2020: -$26.4M → -$27.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$27.5M | -172.3% |
| FY2024 | $38.0M | +160.5% |
| FY2023 | -$62.8M | +40.4% |
| FY2022 | -$105.4M | -52.5% |
| FY2021 | -$69.1M | -161.3% |
| FY2020 | -$26.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More GLUE financial trends
GLUE RevenueGLUE Net incomeGLUE Net marginGLUE Gross profitGLUE Gross marginGLUE Operating incomeGLUE Operating marginGLUE Operating cash flowGLUE Capital expendituresGLUE Return on equityGLUE Stock buybacksGLUE Dividends paidGLUE Total assetsGLUE Total liabilitiesGLUE Shareholders’ equityGLUE overview →